Invitrogen™ Human PKR Synthetic Peptide

Description

• PKR Synthetic Peptide, PEP-0418, from Invitrogen
• PKR is a 68 kDa protein and an IFN-induced serine/threonine protein kinase consisting of two N-terminal RNA-binding regulatory domains and a functional C-terminal serine/threonine protein kinase domain
• Activated by dsRNA produced during viral infections, PKR plays a key role in IFN induced-innate antiviral response, virus-induced apoptosis, cell growth and differentiation
• Upon activation, PKR gets autophosphorylated and catalyzes the phosphorylation of elF2 alpha subunit, which leads to an inhibition of protein synthesis
• PKR induces apoptosis by up-regulating Fas expression and mediates FADD/Caspase-8 death signaling pathway
• Upon viral infection, it functions as a dual protein, sequentially activating both cell survival and cell death pathways using kinase independent and dependent strategies
• PRKR regulates multiple pathways which include NF-kappaB activation, p53, p38, and PDGF signaling pathway
• PKR has been implicated in tumor suppression and malignancy
• To evade the antiviral effects of PKR, viruses have evolved multiple mechanisms, such as the inhibition of PKR by the non-structural protein (NS1) of the influenza virus
• More recently, PKR has been implicated in several neurodegenerative diseases including Alzheimer, Huntington, and amyotrophic lateral sclerosis
• This peptide corresponds to 14 amino acids near the amino terminus of human PKR.PEP-0418 can be used as a blocking peptide with polyclonal antibody PA5-20284.